Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
IPO Year:
Exchange: NYSE
Website: stryker.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/2/2024 | $370.00 → $445.00 | Equal-Weight → Overweight | Morgan Stanley |
| 9/10/2024 | $405.00 | Outperform | Wolfe Research |
| 5/30/2024 | $372.00 | Neutral | Goldman |
| 5/22/2024 | $392.00 | Hold → Buy | Needham |
| 1/31/2024 | $315.00 → $360.00 | Hold → Buy | Canaccord Genuity |
| 10/20/2023 | $345.00 | Buy | ROTH MKM |
| 9/5/2023 | $310.00 → $315.00 | Neutral → Buy | BofA Securities |
| 3/29/2023 | $287.00 | Neutral | UBS |
| 1/25/2023 | Sector Weight | KeyBanc Capital Markets | |
| 1/9/2023 | $240.00 → $284.00 | Sector Perform → Outperform | RBC Capital Mkts |
Portage, Michigan, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK), a global leader in medical technologies, announced today that it has completed the acquisition of Inari Medical, Inc. (NASDAQ:NARI), a company that provides innovative solutions for venous thromboembolism (VTE) clot removal without the use of thrombolytic drugs. The addition of Inari brings an established peripheral vascular position to Stryker in the fast-growing VTE segment. "The acquisition of Inari Medical marks a significant milestone in expanding our interventional endovascular portfolio," said Kevin Lobo, Chair and Chief Executive Officer, Stryker. "We look forward to welcoming the talented Inari team to Stryk
NEW YORK, Feb. 13, 2025 /PRNewswire/ -- Kadant Inc. (NYSE:KAI) will replace Inari Medical Inc. (NASD: NARI) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, February 19. S&P 500 constituent Stryker Corp. (NYSE:SYK) is acquiring Inari Medical in a deal expected to be completed soon, pending final closing conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector February 19, 2025 S&P SmallCap 600 Addition Kadant KAI Industrials February 19, 2025 S&P SmallCap 600 Deletion Inari Medical NARI Health Care For more information about
Portage, Michigan, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) will participate in Citi's 2025 Unplugged Medtech and Life Sciences Access Day on Thursday, February 27, 2025 at Citigroup Headquarters, New York, New York. Stryker's management will represent the Company in a presentation scheduled for 12:15 p.m. Eastern Time. A simultaneous webcast and replay of the Company's presentation will be available on Stryker's website at www.stryker.com. The webcast will be archived on the Investor Relations page of this site. About Stryker Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative pr
Portage, Michigan, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced today that after 14 years of distinguished service, Allan Golston has notified the company that he will not stand for re-election at Stryker's 2025 Annual Meeting of Shareholders, which is expected to be held on May 8, 2025. Golston joined Stryker's Board of Directors in 2011 and served as independent Lead Director from 2016 to 2022. He also served on the Governance and Nominating Committee and as Chair of the Compensation and Human Capital and Audit Committees. "We are grateful for Allan's many contributions to the board over the years and thank him for his strategic guidance and steadfast support of our gr
Portage, Michigan, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.84 per share payable April 30, 2025 to shareholders of record at the close of business on March 31, 2025, representing an increase of 5.0% versus the prior year and unchanged from the previous quarter. About Stryker Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 15
The Issuance of this 10th Patent for TETRANITE® Significantly Expands RevBio's Patent Protection for its Novel Structural Bio Adhesive Technology Platform The United States Patent and Trademark Office recently issued patent 12,178,937 entitled "Compositions and Methods for Adhesion to Surfaces," which constitutes the 10th U.S. patent that covers the TETRANITE bone adhesive technology. This patent expands the protected technology to include injectable mineral-organic structural bone adhesive compositions that comprise alpha tricalcium phosphate. The issuance of this patent complements RevBio's existing U.S. patent 11,638,777, which covers the method of repairing fractured bone using the af
Portage, Michigan, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the fourth quarter and full year of 2024: Fourth Quarter Results Reported net sales increased 10.7% to $6.4 billionOrganic net sales increased 10.2%Reported operating income margin of 9.0%Adjusted operating income margin(1) increased 200 bps to 29.2%Reported EPS decreased 52.7% to $1.41Adjusted EPS(1) increased 15.9% to $4.01 Fourth Quarter Net Sales Growth Overview Reported Foreign Currency Exchange Constant Currency Acquisitions / Divestitures OrganicMedSurg and Neurotechnology 10.6 % (0.5) % 11.1 % 1.0 % 10.1
Portage, Michigan, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK), a global leader in medical technologies, announced today a definitive agreement to sell its U.S. spinal implants business to Viscogliosi Brothers, LLC, a family-owned investment firm specializing in the neuro-musculoskeletal space, to create a newly formed company called VB Spine, LLC. "We believe that the spinal implants business, with its comprehensive portfolio and strong sales channel, will thrive as an independent company," said Kevin A. Lobo, Chair and Chief Executive Officer, Stryker. "With dedicated resources and a focused strategy, the business will be well positioned to succeed as part of Viscogliosi Broth
Portage, Michigan, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced today that Glenn S. Boehnlein will retire from his role as Vice President, Chief Financial Officer. Boehnlein's decision follows an impressive 22-year career at Stryker. Preston Wells, who currently serves as Group CFO for Stryker's Orthopaedics Group, will assume the role of Vice President, Chief Financial Officer effective April 1, 2025. "I want to thank Glenn for his performance drive, strong business partnership, and excellent leadership of the Finance and IT organizations. Glenn is a growth champion who invested in developing talent, including Preston Wells, who has been promoted to Chief Financial Offi
Portage, Michigan, Jan. 17, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) today announced that it is commencing, through a wholly owned subsidiary, Eagle 1 Merger Sub, Inc., a cash tender offer to purchase all of the issued and outstanding shares of common stock of Inari Medical, Inc. (NASDAQ:NARI) for $80.00 per share in cash. The offer is being made pursuant to the previously announced merger agreement, dated as of January 6, 2025, among Stryker, Eagle 1 Merger Sub, Inc and Inari. The tender offer is scheduled to expire at one minute past 11:59 p.m. Eastern Time, on February 18, 2025, unless extended in accordance with the terms of the merger agreement. The tender offer is subject to var
4 - STRYKER CORP (0000310764) (Issuer)
4 - STRYKER CORP (0000310764) (Issuer)
4 - STRYKER CORP (0000310764) (Issuer)
4 - STRYKER CORP (0000310764) (Issuer)
4 - STRYKER CORP (0000310764) (Issuer)
4 - STRYKER CORP (0000310764) (Issuer)
4 - STRYKER CORP (0000310764) (Issuer)
4 - STRYKER CORP (0000310764) (Issuer)
4 - STRYKER CORP (0000310764) (Issuer)
4/A - STRYKER CORP (0000310764) (Issuer)
8-K - STRYKER CORP (0000310764) (Filer)
144 - STRYKER CORP (0000310764) (Subject)
10-K - STRYKER CORP (0000310764) (Filer)
IRANNOTICE - STRYKER CORP (0000310764) (Filer)
8-K - STRYKER CORP (0000310764) (Filer)
8-K - STRYKER CORP (0000310764) (Filer)
424B5 - STRYKER CORP (0000310764) (Filer)
FWP - STRYKER CORP (0000310764) (Subject)
424B5 - STRYKER CORP (0000310764) (Filer)
8-K - STRYKER CORP (0000310764) (Filer)
Morgan Stanley upgraded Stryker from Equal-Weight to Overweight and set a new price target of $445.00 from $370.00 previously
Wolfe Research initiated coverage of Stryker with a rating of Outperform and set a new price target of $405.00
Goldman initiated coverage of Stryker with a rating of Neutral and set a new price target of $372.00
Needham upgraded Stryker from Hold to Buy and set a new price target of $392.00
Canaccord Genuity upgraded Stryker from Hold to Buy and set a new price target of $360.00 from $315.00 previously
ROTH MKM initiated coverage of Stryker with a rating of Buy and set a new price target of $345.00
BofA Securities upgraded Stryker from Neutral to Buy and set a new price target of $315.00 from $310.00 previously
UBS initiated coverage of Stryker with a rating of Neutral and set a new price target of $287.00
KeyBanc Capital Markets initiated coverage of Stryker with a rating of Sector Weight
RBC Capital Mkts upgraded Stryker from Sector Perform to Outperform and set a new price target of $284.00 from $240.00 previously
Portage, Michigan, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK), a global leader in medical technologies, announced today that it has completed the acquisition of Inari Medical, Inc. (NASDAQ:NARI), a company that provides innovative solutions for venous thromboembolism (VTE) clot removal without the use of thrombolytic drugs. The addition of Inari brings an established peripheral vascular position to Stryker in the fast-growing VTE segment. "The acquisition of Inari Medical marks a significant milestone in expanding our interventional endovascular portfolio," said Kevin Lobo, Chair and Chief Executive Officer, Stryker. "We look forward to welcoming the talented Inari team to Stryk
Portage, Michigan, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.84 per share payable April 30, 2025 to shareholders of record at the close of business on March 31, 2025, representing an increase of 5.0% versus the prior year and unchanged from the previous quarter. About Stryker Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 15
Portage, Michigan, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the fourth quarter and full year of 2024: Fourth Quarter Results Reported net sales increased 10.7% to $6.4 billionOrganic net sales increased 10.2%Reported operating income margin of 9.0%Adjusted operating income margin(1) increased 200 bps to 29.2%Reported EPS decreased 52.7% to $1.41Adjusted EPS(1) increased 15.9% to $4.01 Fourth Quarter Net Sales Growth Overview Reported Foreign Currency Exchange Constant Currency Acquisitions / Divestitures OrganicMedSurg and Neurotechnology 10.6 % (0.5) % 11.1 % 1.0 % 10.1
Portage, Michigan, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.84 per share payable January 31, 2025 to shareholders of record at the close of business on December 31, 2024, representing an increase of 5.0% versus the prior year and previous quarter. "We continue to deliver strong financial results, and consistent with our capital allocation priorities we are raising our dividend 5.0%," said Kevin Lobo, Chair and Chief Executive Officer, Stryker. About Stryker Stryker is a global leader in medical technologies and, together with its customers, is driven to make healthcare better. The company offers
Portage, Michigan, Oct. 29, 2024 (GLOBE NEWSWIRE) -- reported operating results for the third quarter of 2024: Third Quarter Results Reported net sales increased 11.9% to $5.5 billionOrganic net sales increased 11.5%Reported operating income margin of 19.7%Adjusted operating income margin(1) increased 130 bps to 24.7%Reported EPS increased 20.0% to $2.16Adjusted EPS(1) increased 16.7% to $2.87 Third Quarter Net Sales Growth Overview Reported Foreign Currency Exchange Constant Currency Acquisitions / Divestitures OrganicMedSurg and Neurotechnology 12.8 % (0.1) % 12.9 % 0.2 % 12.7 %Orthopaedics and Spine 10.7
Portage, Michigan, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced today that it has completed the acquisition of Vertos Medical Inc., a leader in interventional pain management solutions for chronic lower back pain caused by lumbar spinal stenosis. "The acquisition of Vertos Medical enhances our unique, non-surgical solutions for interventionalists addressing chronic lower back pain, while broadening our presence in ambulatory surgery centers," said Andy Pierce, Group President, MedSurg and Neurotechnology, Stryker. "We look forward to enabling physicians with the minimally invasive mild® procedure so patients can reclaim their quality of life." The addition of Vertos Me
PORTAGE, Mich., USA, Sept. 20, 2024 /PRNewswire/ -- Stryker (NYSE:SYK), a global leader in medical technologies, announced today that it has completed the acquisition of NICO Corporation, a privately held company providing a systematic approach to minimally invasive surgery for tumor and intracerebral hemorrhage (ICH) procedures. This acquisition further strengthens Stryker's commitment to neurotechnology through tumor and stroke care. ICH, or bleeding in the brain caused by a ruptured blood vessel, is the deadliest form of stroke, affecting over 3.4 million people annually ar
Portage, Michigan, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.80 per share payable October 31, 2024 to shareholders of record at the close of business on September 30, 2024, representing an increase of 6.7% versus the prior year and unchanged from the previous quarter. About Stryker Stryker is a global leader in medical technologies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in MedSurg, Neurotechnology, Orthopaedics and Spine that help improve patient and healthcare outcomes. Alongside its customers around the world, Stry
SAN JOSE, California, USA, July 31, 2024 /PRNewswire/ -- Stryker (NYSE:SYK), a global leader in medical technologies, announced today that it has completed the acquisition of MOLLI Surgical Inc., a privately held company specializing in the development of wire-free soft tissue localization technology for breast conserving surgery. MOLLI's portfolio further strengthens Stryker's commitment to advancing surgical solutions in breast cancer care. The MOLLI 2 localization system is designed for ease of use and reliability to support a more efficient surgical workflow. The MOLLI Mar
Portage, Michigan, July 30, 2024 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the second quarter of 2024: Second Quarter Results Reported net sales increased 8.5% to $5.4 billionOrganic net sales increased 9.0%Reported operating income margin of 19.4%Adjusted operating income margin(1) increased 30 bps to 24.6%Reported EPS increased 10.9% to $2.14Adjusted EPS(1) increased 10.6% to $2.81 Second Quarter Net Sales Growth Overview Reported Foreign Currency Exchange Constant Currency Acquisitions / Divestitures OrganicMedSurg and Neurotechnology 9.0 % (0.8) % 9.8 % 0.1 % 9.7
SC 13G/A - STRYKER CORP (0000310764) (Subject)
SC 13G/A - STRYKER CORP (0000310764) (Subject)
SC 13G/A - STRYKER CORP (0000310764) (Subject)
SC 13G/A - STRYKER CORP (0000310764) (Subject)
SC 13G/A - STRYKER CORP (0000310764) (Subject)
SC 13G/A - STRYKER CORP (0000310764) (Subject)
SC 13G/A - STRYKER CORP (0000310764) (Subject)
SC 13G/A - STRYKER CORP (0000310764) (Subject)
SC 13G/A - STRYKER CORP (0000310764) (Subject)
SC 13G/A - STRYKER CORP (0000310764) (Subject)
NEW YORK, Feb. 13, 2025 /PRNewswire/ -- Kadant Inc. (NYSE:KAI) will replace Inari Medical Inc. (NASD: NARI) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, February 19. S&P 500 constituent Stryker Corp. (NYSE:SYK) is acquiring Inari Medical in a deal expected to be completed soon, pending final closing conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector February 19, 2025 S&P SmallCap 600 Addition Kadant KAI Industrials February 19, 2025 S&P SmallCap 600 Deletion Inari Medical NARI Health Care For more information about
Portage, Michigan, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced today that Glenn S. Boehnlein will retire from his role as Vice President, Chief Financial Officer. Boehnlein's decision follows an impressive 22-year career at Stryker. Preston Wells, who currently serves as Group CFO for Stryker's Orthopaedics Group, will assume the role of Vice President, Chief Financial Officer effective April 1, 2025. "I want to thank Glenn for his performance drive, strong business partnership, and excellent leadership of the Finance and IT organizations. Glenn is a growth champion who invested in developing talent, including Preston Wells, who has been promoted to Chief Financial Offi
Mr. Scannell and Ms. Lane will Add Valuable Medical Technology, Finance and Corporate Governance Experience to Expanded Eight-Member Board Masimo Corporation (NASDAQ:MASI), a leading global medical innovator, today announced the appointments of Timothy J. Scannell and Wendy E. Lane to the Company's Board of Directors (the "Board"), effective immediately. Following these appointments, the Board will consist of eight directors. Quentin Koffey, Lead Independent Director of Masimo, stated, "We are pleased to welcome Tim and Wendy as our newest independent directors. Both are high-caliber professionals who will bring critical perspectives to the Board and possess expertise that closely aligns
EMERYVILLE, Calif., Sept. 12, 2024 /PRNewswire/ -- Eko Health, a pioneer in applying artificial intelligence (AI) for early detection of heart and lung diseases, today announced the appointment of Brent D. Lang, former Chairman and CEO of Vocera Communications, to its Board of Directors. Lang brings over three decades of healthcare and technology experience, having led Vocera through rapid growth, a successful IPO, and its $3 billion acquisition by Stryker (NYSE:SYK). His strategic vision and proven leadership will guide Eko as it continues to innovate and expand its platform
Sends Letter to Masimo Shareholders and Releases 160-Page Investor Presentation Urges Shareholders to Help Deliver Immediate Change by Voting for Both of Politan's Independent and Ideally Qualified Nominees Darlene Solomon and William Jellison on the WHITE Card Shareholders Can Visit www.AdvanceMasimo.com for Further Information Politan Capital Management (together with its affiliates, "Politan"), an 8.9% shareholder of Masimo Corporation ("Masimo" or the "Company") (NASDAQ:MASI), today sent a letter to the Company's shareholders outlining why a majority of truly independent directors are urgently needed in the Masimo boardroom. Politan also released a detailed investor presentation m
Spineology Inc. ("Spineology" or the "Company"), the leader in ultra-minimally invasive spine surgery, announced today the addition of Emory Rooney as Executive Vice President, Sales. In this role, Rooney will lead U.S. market growth and sales efforts. Rooney comes to Spineology with extensive spine sales experience, having served in Medical Device fields related to spinal implants and navigation for nearly 20 years. "The addition of Emory adds even further conviction about our clear opportunity for growth at Spineology," said Brian Snider, Chief Executive Officer at Spineology. "I have had the opportunity to work with Emory and have seen his impact leading sales teams, building new terri
PALM BEACH GARDENS, Fla., May 12, 2022 (GLOBE NEWSWIRE) -- AeroClean Technologies ("AeroClean" or the "Company") (NASDAQ:AERC), a pathogen elimination technology company harnessing patented UV-C LED technology with Pūrgo™ to significantly reduce and remove harmful pathogens to keep work, play and life going, today announced the appointment of Timothy J. Scannell, former President and Chief Operating Officer at Stryker, to its Board of Directors (the "Board"). On May 11, 2022, the Board appointed Mr. Scannell as a new director on the Board, chair of the Nominating and Corporate Governance Committee and a member of the Compensation Committee. Mr. Scannell brings over 30 years of experienc
FREMONT, Calif., Sept. 1, 2021 /PRNewswire/ -- THINK Surgical, Inc., an innovator in the field of orthopedic surgical robots, today announced the appointment of Stuart F. Simpson as its president and chief executive officer. Mr. Simpson's decades of experience in the medical device industry, particularly his deep understanding of the orthopedics industry and orthopedic surgical robots, makes him the ideal person to lead THINK Surgical. Mr. Simpson had a successful 24-year career at Stryker Corporation (NYSE:SYK) holding roles of increasing responsibility in Europe, Asia Paci
As the pioneer of the first FDA-approved continuous glucose monitor, Dr. Mastrototaro will be integral in advancing the development and regulatory process of the Company's glucose and blood pressure monitoring technology PLEASANTON, CA / ACCESSWIRE / March 25, 2021 / Today, Movano Inc. (NASDAQ:MOVE), a health technology company designing devices that empower individuals to optimize their health in order to prevent and better manage chronic diseases, announced current Director, Dr. John Mastrototaro, will join the Company as CEO, effective April 1, 2021. Movano's founder and current CEO, Michael Leabman, will become the Company's CTO and will remain on the Company's Board of Directors. Dr. M
WARREN, N.J., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, today announced the appointment of Julie Krop, M.D., Chief Medical Officer of Freeline Therapeutics (NASDAQ: FRLN), and Marco Taglietti, M.D., Director, President and Chief Executive Officer of SCYNEXIS (NASDAQ: SCYX), to the Board of Directors of the Company effective February 10, 2021. Aquestive also announced the resignation of Douglas K. Bratton from the Board of Directors after more than 17 years of service. Aquestive’s Board of Directors